Pathogenetic mechanisms of development of myocardial pathology in patients with malignant tumors: the current state of the problem
https://doi.org/10.18087/cardio.2020.2.n985
Abstract
The myocardium, which has a high metabolic activity, responds to metabolic disorders and energy imbalance induced by a growing malignant tumor. In addition, the tumor itself can produce substances that directly affect metabolic processes and the life cycle of cells not involved in the neoplastic process, including cardiomyocytes. This review summarized and systematized current data on individual aspects of detrimental effects of oncogenes and tumor-related factors on the heart muscle and morpho-functional changes in the cardiovascular system of oncology patients. Also, the authors described in detail development of these pathogenetic mechanisms.
About the Authors
A. G. Obrezan
St. Petersburg State University, SOGAZ International Medical Center, St. Petersburg
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
N. V. Shcherbakova
SOGAZ International Medical Center, St. Petersburg
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Burch GE, Phillips JH, Ansari A. The Cachectic Heart. Diseases of the Chest. 1968;54(5):403–9. DOI: 10.1378/chest.54.5.403
2. Houten L, Reilley AA. An investigation of the cause of death from cancer. Journal of Surgical Oncology. 1980;13(2):111–6. DOI: 10.1002/jso.2930130205
3. Mamidanna R, Nachiappan S, Bottle A, Aylin P, Faiz O. Defining the timing and causes of death amongst patients undergoing colorectal resection in England. Colorectal Disease. 2016;18(6):586–93. DOI: 10.1111/codi.13224
4. McBride W, Jackman JD, Grayburn PA. Prevalence and clinical characteristics of a high cardiac output state in patients with multiple myeloma. The American Journal of Medicine. 1990;89(1):21–4. DOI: 10.1016/0002-9343(90)90092-R
5. Drott C, Lundholm K. Glucose uptake and amino acid metabolismin perfused hearts from tumor-bearing rats. Journal of Surgical Research. 1990;49(1):62–8. DOI: 10.1016/0022-4804(90)90112-F
6. Maron BJ. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI: 10.1161/CIRCULATIONAHA.106.174287
7. Belenkov Yu.N., Oganov R.G. Cardiology: National guide. – M.: GEOTAR-Media; 2011. – 1232 p. ISBN 978-5-9704-2767-5
8. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. The Journal of General Physiology. 1927;8(6):519–30. DOI: 10.1085/jgp.8.6.519
9. Shapot V.S. Biochemical aspects of tumor growth. -M.: Medicine;1975. 304 p. [Russian: Шапот В.С. Биохимические аспекты опухолевого роста. М.: Медицина, 1975. 304c]
10. Anichkov N.M., Kvetnoy I.M., Konovalov S.S. Biology of tumor growth. – SPb.: Prime-Euroznak; M.: Olma-Press;2004. – 216 p. ISBN 5-94946-090-1
11. Humberstone DA, Shaw JH. Metabolism in hematologic malignancy. Cancer. 1988;62(8):1619–24. DOI: 10.1002/1097-0142(19881015)62:8<1619::aid-cncr2820620827>3.0.co;2-c
12. Dempsey DT, Feurer ID, Knox LS, Crosby LO, Buzby GP, Mullen JL. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer. 1984;53(6):1265–73. DOI: 10.1002/1097-0142(19840315)53:6<1265::aid-cncr2820530609>3.0.co;2-2
13. Ado A.D. Pathological physiology. – M.: Triada-X;2000. – 573 p. https://studfile.net/preview/1818857/]. ISBN 5-8249-0023-X
14. Homburger F, Young NF. Hypoproteinemia in patients with gastric cancer; its persistence after operation in the presence of body tissue repletion. Blood. 1948;3(12):1460–71. PMID: 18893858
15. Jarnum S, Schwartz M. Hypoalbuminemia in gastric carcinoma. Gastroenterology. 1960; 38: 769–76. PMID: 14406821
16. Casiero D, Frishman WH. Cardiovascular Complications of Eating Disorders. Cardiology in Review. 2006;14(5):227–31. DOI: 10.1097/01.crd.0000216745.96062.7c
17. Cosper PF, Leinwand LA. Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner. Cancer Research. 2011;71(5):1710–20. DOI: 10.1158/0008-5472.CAN-10-3145
18. Tian M, Asp ML, Nishijima Y, Belury M. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. International Journal of Oncology. 2011;39(5):1321–6. DOI: 10.3892/ijo.2011.1150
19. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury. Cardiac alterations in cancer-induced cachexia in mice. International Journal of Oncology. 2010;37(2):347–53. DOI: 10.3892/ijo_00000683
20. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal. 2014;35(14):932–41. DOI: 10.1093/eurheartj/eht302
21. Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M et al. Myocardial dysfunction in an animal model of cancer cachexia. Life Sciences. 2011;88(9–10):406–10. DOI: 10.1016/j.lfs.2010.12.010
22. Sweeney M, Yiu A, Lyon AR, et al. Cardiac Atrophy and Heart Failure in Cancer. Cardiac Failure Review. 2017;3(1):62–6. DOI: 10.15420/cfr.2017:3:2
23. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F et al. Increased Muscle Proteasome Activity Correlates with Disease Severity in Gastric Cancer Patients. Annals of Surgery. 2003;237(3):384–9. DOI: 10.1097/01.SLA.0000055225.96357.71
24. Olbinskaya L.I., Ignatenko S.B. The role of cytokine aggression in the pathogenesis of cardiac cachexia syndrome in patients with chronic heart failure. Russian Heart Failure Journal. 2001;2 (3):132–4.
25. Padrão AI, Moreira-Gonçalves D, Oliveira PA, Teixeira C, Faustino-Rocha AI, Helguero L et al. Endurance training prevents TWEAK but not myostatin-mediated cardiac remodelling in cancer cachexia. Archives of Biochemistry and Biophysics. 2015; 567: 13– 21. DOI: 10.1016/j.abb.2014.12.026
26. Neylon CB, Bryant SM, Little PJ, Bobik A. Transforming Growth Factor-β1 Regulates the Expression of Ryanodine-Sensitive Ca2+ Oscillations in Cardiac Myocytes. Biochemical and Biophysical Research Communications. 1994;204(2):678–84. DOI: 10.1006/bbrc.1994.2513
27. Hinch ECA, Sullivan-Gunn MJ, Vaughan VC, McGlynn MA, Lewandowski PA. Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice. Journal of Cachexia, Sarcopenia and Muscle. 2013;4(4):287–93. DOI: 10.1007/s13539-013-0116-8
28. Egan D, Kim J, Shaw RJ, Guan K-L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy. 2011;7(6):643–4. DOI: 10.4161/au-to.7.6.15123
29. Manne NDPK, Lima M, Enos RT, Wehner P, Carson JA, Blough E. Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse. International Journal of Oncology. 2013;42(6):2134–40. DOI: 10.3892/ijo.2013.1893
30. Dang CV. Links between metabolism and cancer. Genes & Development. 2012;26(9):877–90. DOI: 10.1101/gad.189365.112
31. Murphy KT. The pathogenesis and treatment of cardiac atrophy in cancer cachexia. American Journal of Physiology-Heart and Circulatory Physiology. 2016;310(4):H466–77. DOI: 10.1152/ajpheart.00720.2015
32. Nomura DK, Cravatt BF. Lipid metabolism in cancer. Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids. 2013;1831(10):1497–8. DOI: 10.1016/j.bbalip.2013.08.001
33. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Research. 1953;13(1):27–9. PMID: 13032945
34. Lingwood D, Simons K. Lipid Rafts as a Membrane-Organizing Principle. Science. 2010;327(5961):46–50. DOI: 10.1126/science.1174621
35. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery. 2007;6(7):541–55. DOI: 10.1038/nrd2221
36. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS et al. Lipid Bodies Are Reservoirs of Cyclooxygenase-2 and Sites of Prostaglandin-E2 Synthesis in Colon Cancer Cells. Cancer Research. 2008;68(6):1732–40. DOI: 10.1158/0008-5472.CAN-07-1999
37. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer and Prostatic Diseases. 2006;9(3):230–4. DOI: 10.1038/sj.pcan.4500879
38. Khasawneh J, Schulz MD, Walch A, Rozman J, de Angelis MH, Klingenspor M et al. Inflammation and mitochondrial fatty acid -oxidation link obesity to early tumor promotion. Proceedings of the National Academy of Sciences. 2009;106(9):3354–9. DOI: 10.1073/pnas.0802864106
39. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature Reviews Cancer. 2006;6(3):184–92. DOI: 10.1038/nrc1819
40. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S et al. SREBP Activity Is Regulated by mTORC1 and Contributes to AktDependent Cell Growth. Cell Metabolism. 2008;8(3):224–36. DOI: 10.1016/j.cmet.2008.07.007
41. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes & Development. 2000;14(1):34–44. PMID: 10640274
42. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7(1):77–85. DOI: 10.1016/j.ccr.2004.11.022
43. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology. 1996;16(9):4604–13. DOI: 10.1128/MCB.16.9.4604
44. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer. 2008;8(9):705–13. DOI: 10.1038/nrc2468
45. Santos CR, Schulze A. Lipid metabolism in cancer: Lipid metabolism in cancer. FEBS Journal. 2012;279(15):2610–23. DOI: 10.1111/j.1742-4658.2012.08644.x
46. Goh J, Endicott E, Ladiges WC. Pre-tumor exercise decreases breast cancer in old mice in a distance-dependent manner. American Journal of Cancer Research. 2014;4(4):378–84. PMID: 25057440
47. Krivchik A.A., Vismont F.I., Zhadan S.A. Typical forms of structural-functional subcellular organelles in case of damage. – Minsk: BSMU;2004. – 52 p. ISBN 985-462-298-3
48. Fermoselle C, García-Arumí E, Puig-Vilanova E, Andreu AL, Urtreger AJ, de Kier Joffé EDB et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice: Mitochondrial respiratory chain dysfunction in cachexia. Experimental Physiology. 2013;98(9):1349–65. DOI: 10.1113/expphysiol.2013.072496
49. Marin-Corral J, Fontes CC, Pascual-Guardia S, Sanchez F, Olivan M, Argilés JM et al. Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants & Redox Signaling. 2010;12(3):365–80. DOI: 10.1089/ars.2009.2818
50. Carew JS, Huang P. Mitochondrial defects in cancer. Molecular Cancer. 2002;1(1):9. DOI: 10.1186/1476-4598-1-9
51. Berstein L.M., Prokhorova V.I., Konoplya E.F. Cancer and cyclic nucleotides: tumor growth mechanisms, hormone sensitivity of tumor tissue, clinical oncology problems. -Minsk: Science and Technology;1993. – 230 p. ISBN 978-5-343-00838-8
52. Ostrovsky Yu.M. Active centers and groupings in the thiamine molecule. -Minsk: Science and Technology;1975. 423 p.
53. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World Journal of Gastroenterology. 2005;11(9):1251. DOI: 10.3748/wjg.v11.i9.1251
54. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. The American Journal of Clinical Nutrition. 2006;83(6):1345–50. DOI: 10.1093/ajcn/83.6.1345
55. Makeeva T.K., Galkin A.A. Trofological status of patients with stomach cancer. Bulletin of St. Petersburg State University. Medicine. 2008; S1:105–17.
56. Esper DH, Harb WA. The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations. Nutrition in Clinical Practice. 2005;20(4):369–76. DOI: 10.1177/0115426505020004369
57. Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W et al. Cardiovascular Function and Predictors of Exercise Capacity in Patients with Colorectal Cancer. Journal of the American College of Cardiology. 2014;64(13):1310–9. DOI: 10.1016/j.jacc.2014.07.948
58. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer. 2004;40(15):2293–306. DOI: 10.1016/j.ejca.2004.06.019
59. Acher PL, Al-Mishlab T, Rahman M, Bates T. Iron-deficiency anaemia and delay in the diagnosis of colorectal cancer. Colorectal Disease. 2003;5(2):145–8. DOI: 10.1046/j.1463-1318.2003.00415.x
60. Blyndar V.N., Zubrikhina G.N., Matveyeva I.I. Algorithm of modern laboratory diagnostics of anemic syndrome in oncological patients. Russian Clinical Laboratory Diagnostics. 2012;7:19–24.
61. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematology/Oncology Clinics of North America. 1996;10(2):365–76. DOI: 10.1016/S0889-8588(05)70343-9
62. Sheptulin A.A. Bleeding from the lower sections of the gastrointestinal tract. Supplement RMJ “Diseases of the Digestive system”. 2000;2:36–43.
63. Novik A.V. Anemia and metabolic disorders in cancer patients. Practical Oncology. 2009;10(3):131–40.
64. Moiseev S.V. Capacities of somatostatin analogues to treat castration-resistant prostate cancer. P.A. Herzen Journal of Oncology. 2012;1(1):77–82.
65. Goncharova E.V., Govorin A.V., Kuzmin A.G., Barkan V.S., Filev A.P. Структурно-функциональные показатели миокарда у больных хронической железодефицитной анемией. Kardiologiia. 2008;48 (5):46–50.
66. Kripak O.N. Features of changes in systemic and intracardiac hemodynamics in patients with myocardial dystrophy of various origin. Bulletin of the Russian Military Medical Academy. 2009;1(25):125–30.
67. Wakui A. Electrolyte abnormalities associated with cancer: a review. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 1986;13(6):2031–8. PMID: 3521493
68. Berghmans T. Hyponatremia related to medical anticancer treatment. Supportive Care in Cancer. 1996;4(5):341–50. DOI: 10.1007/BF01788840
69. Onitilo AA, Kio E, Doi SAR. Tumor-Related Hyponatremia. Clinical Medicine & Research. 2007;5(4):228–37. DOI: 10.3121/cmr.2007.762
70. Shapiro J, Richardson GE. Hyponatremia of malignancy. Critical Reviews in Oncology/Hematology. 1995;18(2):129–35. DOI: 10.1016/1040-8428(94)00126-E
71. Jansson B. Potassium, sodium, and cancer: a review. Journal of Environmental Pathology, Toxicology and Oncology. 1996;15(2–4):65–73. PMID: 9216787
72. Semenova A.I. Hypercalcemia and tumor disintegration syndrome. Practical Oncology. 2006; 7(2(26)):101–7.
73. Lukianov S.V., Alubaev S.A., Alekseeva G.A., Soloshenko I.N. Diagnosis and treatment of parathyroid gland tumors. Kuban Scientific Medical Bulletin. 2013;4 (139):73– 5.
74. Motellón JL, Jiménez FJ, de Miguel F, Jaras MJ, Diaz A, Hurtado J et al. Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy. Clinica Chimica Acta. 2000;290(2):189–97. DOI: 10.1016/S0009-8981(99)00181-3
75. Ralston SH. Cancer-Associated Hypercalcemia: Morbidity and Mortality: Clinical Experience in 126 Treated Patients. Annals of Internal Medicine. 1990;112(7):499–504. DOI: 10.7326/0003-4819-112-7-499
76. Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, Sørensen HT. Atrial Fibrillation as a Marker of Occult Cancer. PLoS ONE. 2014;9(8): e102861. DOI: 10.1371/journal.pone.0102861
77. Yeh E, Ewer MS. Cancer and the Heart. 2nd Edition. People’s Medical Publishing House USA Ltd (PMPH);2013. – 550 p. ISBN 978-1-60795-219-0
78. Rahman F, Ko D, Benjamin EJ. Association of Atrial Fibrillation and Cancer. JAMA Cardiology. 2016;1(4): 384. DOI: 10.1001/jamacardio.2016.0582
79. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438–44. DOI: 10.1016/j.hrthm.2009.12.009
80. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10. DOI: 10.1161/01.CIR.0000103131.70301.4F
81. Goyal A, Terry MB, Jin Z, Siegel AB. C-Reactive Protein and Colorectal Cancer Mortality in U.S. Adults. Cancer Epidemiology Biomarkers & Prevention. 2014;23(8):1609–18. DOI: 10.1158/1055-9965.EPI-13-0577
82. Mühlfeld C, Das SK, Heinzel FR, Schmidt A, Post H, Schauer S et al. Cancer Induces Cardiomyocyte Remodeling and Hypoinnervation in the Left Ventricle of the Mouse Heart. PLoS ONE. 2011;6(5): e20424. DOI: 10.1371/journal.pone.0020424
83. Asamura H, Naruke T, Tsuchiya R, Goya T, Kondo H, Suemasu K. What are the risk factors for arrhythmias after thoracic operations? A retrospective multivariate analysis of 267 consecutive thoracic operations. The Journal of Thoracic and Cardiovascular Surgery. 1993;106(6):1104–10. PMID: 8246546
84. vonKnorringJ,LepäntaloM,LindgrenL,LindforsO.Cardiac arrhythmias and myocardial ischemia after thoracotomy for lung cancer. The Annals of Thoracic Surgery. 1992;53(4):642–7. DOI: 10.1016/0003-4975(92)90325-X
85. SørensenHT,SværkeC,FarkasDK,ChristiansenCF,Pedersen L, Lash TL et al. Superficial and deep venous thrombosis, pul-monary embolism and subsequent risk of cancer. European Journal of Cancer. 2012;48(4):586–93. DOI: 10.1016/j.ejca.2011.10.03286.
86. Shimizu K, Miura Y, Meguro Y, Noshiro T, Ohzeki T, Kusakari T et al. QT prolongation with torsade de pointes in pheochromocytoma. American Heart Journal. 1992;124(1):235–9. DOI: 10.1016/0002-8703(92)90954-T
87. Sordillo PP, Sordillo DC, Helson L. Review: The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. In Vivo (Athens, Greece). 2015;29(6):619–36. PMID: 26546519
88. Walker G, Wilcock A, Carey AM, Manderson C, Weller R, Crosby V. Prolongation of the QT interval in palliative care patients. Journal of Pain and Symptom Management. 2003;26(3):855–9. DOI: 10.1016/S0885-3924(03)00313-0
89. Haine SE, Miljoen H p., Blankoff I, Vrints CJ. Atrioventricular Dissociation due to Pheochromocytoma in a Young Adult. Clinical Cardiology. 2010;33(12): e65–7. DOI: 10.1002/clc.20645
90. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nature Reviews Cancer. 2015;15(9):563–72. DOI: 10.1038/nrc3978
91. Bertero E, Canepa M, Maack C, Ameri P. Linking Heart Failure to Cancer: Background Evidence and Research Perspectives. Circulation. 2018;138(7):735–42. DOI: 10.1161/CIRCULATIONAHA.118.033603
92. Bobrov L.L., Novik A.A., Obrezan A.G., Krysjuk O.B. System hemodynamics in patients with lymphomas. Bulletin of the Russian Military Medical Academy. 2000; 1: 58–63.
93. Shevchenko Yu.L., Bobrov L.L., Novik A.A., Obrezan A.G., Krysjuk O.B. Changes in diastolic function of the left ventricle t in patients with non-Hodgkin’s lymphomas. Kardiologiia. 2001; 41(9): 51–5.
94. Greci LS, Rashkow A. High-Output Cardiac Failure in a Patient with Prostate Cancer. Congestive Heart Failure. 2001; 7(4): 220–2. DOI: 10.1111/j.1527-5299.2001.01010.x
95. Plummer C, Driessen C, Szabo Z, Mateos M-V. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer Journal. 2019; 9(3): 26. DOI: 10.1038/s41408-019-0183-y
96. Robin J, Fintel B, Pikovskaya O, Davidson C, Cilley J, Flaherty J. Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature. Journal of Medical Case Reports. 2008; 2(1):229. DOI: 10.1186/1752-1947-2-229
97. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S et al. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018;138(7):678–91. DOI: 10.1161/CIRCULATIONAHA.117.030816
98. HasinT,GerberY,McNallanSM,WestonSA,KushwahaSS, Nelson TJ et al. Patients with Heart Failure Have an Increased Risk of Incident Cancer. Journal of the American College of Cardiology. 2013;62(10):881–6. DOI: 10.1016/j.jacc.2013.04.088
99. ManikhasG.M.,HanevichM.D.,ObrezanA.G.,Vashkurov S.M., Lagoshnyak N.V., Khazov A.V. Problems of diagnosis and preoperative correction of concomitant therapeutic pathology in cancer patients. Problems in oncology. 2013; 59 (3 Suppl): 490–1. http://фотодитазин.рф/upload/iblock/0b7/0b7ca399fd804bf233a34d54d01b1737.pdf
Review
For citations:
Obrezan A.G., Shcherbakova N.V. Pathogenetic mechanisms of development of myocardial pathology in patients with malignant tumors: the current state of the problem. Kardiologiia. 2020;60(2):142-154. https://doi.org/10.18087/cardio.2020.2.n985
Views:
1561
Email this article 
Post a Comment 
